Company news

Amgen Inc. news in 2023

Amgen Inc.'s news releases, calls and decks from 2023, newest first.

View company

Amgen provides regulatory update on status of LUMAKRAS® (sotorasib)

December 25, 2023

Amgen to sponsor the Irish Open

December 13, 2023

Amgen announces executive appointments to accelerate innovation

December 13, 2023

FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer

December 12, 2023

Amgen announces 2024 first quarter dividend increase to $2.25 per share

December 11, 2023

Amgen highlights hematology portfolio at ASH 2023

December 7, 2023

Amgen to present at the evercore isi healthconx conference

November 21, 2023

Amgen presents new cardiovascular research at AHA 2023

November 9, 2023

Amgen presents new research in early psoriatic arthritis at ACR 2023

November 6, 2023

Amgen presents new data from Phase 2 trial of dazodalibep in Sjögren's syndrome at ACR 2023

November 6, 2023

Amgen presents new data that show blood pressure decreases for adults treated with KRYSTEXXA® (pegloticase)

November 1, 2023

Amgen to present data at ACR 2023 across expanded rheumatology pipeline and portfolio

October 31, 2023

Amgen reports third quarter financial results

October 30, 2023

Amgen announces webcast of 2023 third quarter financial results

October 24, 2023

Amgen announces 2023 fourth quarter dividend

October 23, 2023

Amgen presents new LUMAKRAS® (sotorasib) plus Vectibix® (panitumumab) data in patients with KRAS G12C-mutated metastatic colorectal cancer

October 21, 2023

Amgen presents new tarlatamab data in small cell lung cancer

October 19, 2023

Amgen to webcast investor call at esmo 2023

October 18, 2023

Amgen to present new research from oncology portfolio and pipeline at ESMO 2023

October 15, 2023

Amgen completes acquisition of Horizon Therapeutics plc

October 5, 2023

Amgen launches Partners of Choice network of eight leading oncology academic centers

September 19, 2023

Amgen presents new LUMAKRAS® (sotorasib) plus chemotherapy data in first-line KRAS G12C NSCLC at wclc

September 9, 2023

Amgen to present at the morgan stanley global healthcare conference

September 6, 2023

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

August 31, 2023

Amgen to present at the 2023 wells fargo healthcare conference and the citi global healthcare conference

August 30, 2023

Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

August 25, 2023

Amgen to discuss application for LUMAKRAS® (sotorasib) for the treatment of KRAS G12C-positive NSCLC at FDA advisory committee meeting

August 20, 2023

Amgen reports second quarter financial results

August 2, 2023

Amgen announces 2023 third quarter dividend

July 31, 2023

Amgen announces webcast of 2023 second quarter financial results

July 30, 2023

FDA grants full approval for BLINCYTO® (blinatumomab) to treat minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia

June 20, 2023

Amgen to present at the goldman sachs 44th annual global healthcare conference

June 8, 2023

Amgen presents new LUMAKRAS® (sotorasib) CodeBreaK 200 CNS data at ASCO 2023

June 3, 2023

Amgen presents new scientific and clinical research across its diverse oncology portfolio and pipeline at ASCO 2023

May 31, 2023

Amgen presents new research on Otezla® (apremilast) in psoriatic arthritis at EULAR 2023

May 29, 2023

Amgen to present at the td cowen 4th annual oncology innovation summit

May 25, 2023

Amgen responds to FTC action re: proposed acquisition of Horizon Therapeutics

May 15, 2023

Amgen and TScan Therapeutics announce collaboration to identify novel targets in crohn's disease

May 8, 2023

New data from Amgen's Prolia® (denosumab) demonstrates significant reduction in osteoporotic fracture risk compared to alendronate

May 7, 2023

Amgen to present at the 2023 bank of america merrill lynch global healthcare conference

May 2, 2023

Amgen reports first quarter financial results

April 26, 2023

Amgen announces webcast of 2023 first quarter financial results

April 20, 2023

Amgen wins patent appeal on Otezla® (apremilast)

April 18, 2023

Amgen to present at the 33rd annual oppenheimer healthcare conference

March 8, 2023

Amgen announces 2023 second quarter dividend

March 6, 2023

Amgen to present at the 43rd annual td cowen healthcare conference

March 2, 2023

Amgen to present new Repatha® (evolocumab) and olpasiran data at acc

February 28, 2023

Amgen announces cardiovascular study to evaluate Association between lipoprotein(a) and cardiovascular risk in African Americans

February 21, 2023

Amgen to present at the 2023 svb securities global biopharma conference

February 8, 2023

TEZSPIRE® approved for self-administration in the U.S. with a new pre-filled pen

February 1, 2023

Older news releases →

Calls in 2023

Decks in 2023